SBI Capital Markets Limited (Manager to the Open Offer) has submitted to the Exchange a copy of Detailed Public Statement in terms of Regulation 3(1) and Regulation 4 read with Regulation 13(4), Regulation 15(2) and other applicable Regulations of The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, to the Public Shareholders of Bliss GVS Pharma Limited (Target Company).
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SBI Capital Markets Limited, acting as the Manager to the Open Offer, has filed a Detailed Public Statement with the Exchange on behalf of an acquirer for the public shareholders of Bliss GVS Pharma Limited. The filing is made under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, specifically under Regulations 3(1) and 4, which are triggered when an entity crosses the 25% shareholding threshold or seeks to take control of a listed company. This is a mandatory disclosure step that must precede the actual open offer to public shareholders. The detailed statement will contain key details such as the acquirer's identity, offer price, number of shares being offered, and the timeline of the open offer window.
Shareholders should watch for the offer price and size details in the Detailed Public Statement, as this signals a potential change in ownership or control of the company. An open offer typically allows existing public shareholders an opportunity to exit at the offer price, which may or may not be at a premium to market price.